C-Peptide

Base Information

• Chemical Name: C-Peptide
• CAS No.: 33017-11-7
• Molecular Formula: C129H211N35O48
• Molecular Weight: 3020.26
• UNII: O2J76Y002M
• ChEMBL ID: CHEMBL4594409
• DSSTox Substance ID: DTXSID00186651
• Wikipedia: C-peptide
• Mol file: 33017-11-7.mol

Synonyms:C Peptide;C Peptide, Proinsulin;C-Peptide;C-Peptide, Proinsulin;Connecting Peptide;Proinsulin C Peptide;Proinsulin C-Peptide

Chemical Property of C-Peptide

Chemical Property:

• Boiling Point: 2864.4±65.0 °C(Predicted)
• PSA: 1318.06000
• Density: 1.328±0.06 g/cm3(Predicted)
• LogP: -1.67420
• Storage Temp.: −20°C
• Solubility.: Soluble in 1% acetic acid at 1mg/ml
• XLogP3: -12.6
• Hydrogen Bond Donor Count: 41
• Hydrogen Bond Acceptor Count: 49
• Rotatable Bond Count: 101
• Exact Mass: 3019.5179284
• Heavy Atom Count: 212
• Complexity: 7190

Purity/Quality:

97% ^*data from raw suppliers

C-Peptide, Human ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CC(C)CC(C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)O)NC(=O)C1CCCN1C(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)CNC(=O)C(C)NC(=O)CNC(=O)C2CCCN2C(=O)CNC(=O)CNC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CCC(=O)O)N
• Isomeric SMILES: C[C@@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)N
• Recent ClinicalTrials: Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes
• Recent EU Clinical Trials: A Phase 2b, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of CBX129801 (Ersatta?), Long-Acting Synthetic C-Peptide, in Type 1 Diabetes Mellitus Subjects with Mild to Moderate Diabetic Peripheral Neuropathy